Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
about
Epigenome engineering in cancer: fairytale or a realistic path to the clinic?Fabrication, characterization, and biological evaluation of anti-HER2 indocyanine green-doxorubicin-encapsulated PEG-b-PLGA copolymeric nanoparticles for targeted photochemotherapy of breast cancer cellsSynthesis, characterization, and biological verification of anti-HER2 indocyanine green-doxorubicin-loaded polyethyleneimine-coated perfluorocarbon double nanoemulsions for targeted photochemotherapy of breast cancer cellsPrognostic importance and therapeutic implications of PAK1, a drugable protein kinase, in gastroesophageal junction adenocarcinoma.Autophagy Protects from Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids.Presence of human papillomavirus in breast cancer and its association with prognostic factors.HER2 status in molecular apocrine breast cancer: associations with clinical, pathological, and molecular features.Physical Intimacy of Breast Cancer Cells with Mesenchymal Stem Cells Elicits Trastuzumab Resistance through Src ActivationSynthesis, Characterization, and Biological Evaluation of Anti-HER2 Indocyanine Green-Encapsulated PEG-Coated PLGA Nanoparticles for Targeted Phototherapy of Breast Cancer Cells.t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib.Eavesdropping on altered cell-to-cell signaling in cancer by secretome profilingSignaling Pathway of GP88 (Progranulin) in Breast Cancer Cells: Upregulation and Phosphorylation of c-myc by GP88/Progranulin in Her2-Overexpressing Breast Cancer CellsCDC25A protein stability represents a previously unrecognized target of HER2 signaling in human breast cancer: implication for a potential clinical relevance in trastuzumab treatment.Discovery of a Potential HER2 Inhibitor from Natural Products for the Treatment of HER2-Positive Breast CancerImproved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targetingDownregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer.Multidrug-resistant breast cancer: current perspectives.Small-molecule inhibitors of DNA damage-repair pathways: an approach to overcome tumor resistance to alkylating anticancer drugs.Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.Mechanisms of tumor cell resistance to the current targeted-therapy agents.Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [(89)Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model.Hyaluronan expression in primary and secondary brain tumors.HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosisrs12976445 variant in the pri-miR-125a correlates with a lower level of hsa-miR-125a and ERBB2 overexpression in breast cancer patients.Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian CancerSP1 promotes tumor angiogenesis and invasion by activating VEGF expression in an acquired trastuzumab‑resistant ovarian cancer model.Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer.Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition.Construction and characterization of a new chimeric antibody against HER2.The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2.
P2860
Q26861350-50CFD49D-5BF0-4F1E-9FBC-A4482A231784Q33587331-34676933-124A-4681-B277-30A2135BB383Q33706296-CB2CEB08-A7A5-4D83-8B89-A387BAF2A3FAQ35043996-26A783C2-3C60-4044-9582-7C1B61FDD94DQ35770542-84D693BF-3AD3-4ECB-BE96-D2738AFCE5C6Q35828250-E7E0197A-9EA3-46D6-B68C-A6B97C8F880CQ36014239-449D0614-576C-4662-9E14-D49E436A7305Q36034029-3BB21F10-6ABF-49A3-8E73-63083DAE7C72Q36220170-A7ED4EFB-124F-4347-A5CB-9621469B99C4Q36545095-2EBBDE5A-869C-479D-B40B-AEF782973ABDQ36836135-4E6A9C99-9057-46A2-AA19-2F9111B149EAQ36878094-BFE25CBF-C82C-4A87-A840-9A9D469AB066Q36881905-87303834-506D-45CC-8CBD-76A38ADAB93AQ37134449-91FFF791-C297-4C0D-BF13-36959AD6E308Q37138332-DB5DAFAB-F602-415B-A53A-080196C30FF5Q37317395-2280BBAD-6CDE-4224-A17B-55F6B7DDA944Q37593383-079B290A-30BB-4162-B270-D0233F38DF8FQ38019607-2B4977EE-4BC2-42FD-BDF0-5D058F406113Q38399446-436EE814-AB62-414F-A310-7E2F13F03F3CQ38828353-32B173A9-54DF-48C2-A48A-327988362507Q38901000-6EA6F1B8-6323-4020-B524-F0C15CC1AFE4Q40169267-0D3A4FBC-CD62-44D0-A2BD-B49FA71F3868Q41909130-16CD1FC7-B5BF-40CE-A30A-86EF47811985Q41948441-0BE0D612-DD56-4BCA-9942-A296596206ACQ42281218-6426D2C3-2AE5-4893-86CF-9C155FB3638CQ42660155-0F771B1F-3706-40C0-B62F-0E4FD9715B03Q49358317-4988E5BB-A627-4929-ABE9-5AA4A678FB82Q49544395-E5A049EE-1ABB-4D2E-9FA8-965751ECFF90Q49567029-8E769246-FDEE-4076-9BC5-182A5572305FQ50856283-A82C3D02-273A-4ECE-932E-150515057CA2Q55183005-13457B95-03EB-457E-8DD3-410CF5A5DE4B
P2860
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
@ast
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
@en
type
label
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
@ast
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
@en
prefLabel
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
@ast
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
@en
P2860
P356
P1476
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
@en
P2093
Gabriel L Fiszman
María A Jasnis
P2860
P304
P356
10.4061/2011/352182
P577
2011-09-06T00:00:00Z